Coxevac Evrópusambandið - íslenska - EMA (European Medicines Agency)

coxevac

ceva santé animale - óvirkt coxiella burnetii bóluefni, stofn nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Neocolipor Evrópusambandið - íslenska - EMA (European Medicines Agency)

neocolipor

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - lækkun á eiturverkunum á smábörnum með nýbura, sem stafar af e. coli stofnar, sem tjá límið f4ab, f4ac, f4ad, f5, f6 og f41, á fyrstu dögum lífsins.

Porcilis PCV ID Evrópusambandið - íslenska - EMA (European Medicines Agency)

porcilis pcv id

intervet international b.v. - svín circovirus tegund 2 orf2 undireiningu mótefnavaka - immunologicals for suidae, inactivated viral vaccines - svín - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

ProteqFlu-Te Evrópusambandið - íslenska - EMA (European Medicines Agency)

proteqflu-te

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / vcp 2242 veira / vcp1529 veira / vcp1533 veira / vcp3011 veira - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - hestar - virk ónæmisaðgerð hrossa fjögurra mánaða eða eldri gegn hestum inflúensu til að draga úr klínískum einkennum og útskilnaði veiru eftir sýkingu og gegn stífkrampa til að koma í veg fyrir dánartíðni.

Suvaxyn CSF Marker Evrópusambandið - íslenska - EMA (European Medicines Agency)

suvaxyn csf marker

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - svín - fyrir virkan ónæmingu svína frá 7 vikna aldri til að koma í veg fyrir dauðsföll og draga úr sýkingu og sjúkdómum af völdum svínapestarveiru (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

Zulvac 1+8 Ovis Evrópusambandið - íslenska - EMA (European Medicines Agency)

zulvac 1+8 ovis

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - sauðfé - virk ónæmisaðgerð sauðfjár frá 1. 5 mánaða aldur til að koma í veg fyrir veirublæði af völdum blátunguveiru, sermisgerðar 1 og 8. upphaf ónæmis: 21 dagar eftir að aðalbólusetningaráætluninni er lokið. lengd ónæmis: 12 mánuðir.

Vepured Evrópusambandið - íslenska - EMA (European Medicines Agency)

vepured

laboratorios hipra, s.a. - raðbrigða verotoxin 2e af e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svín - virk ónæmisaðgerð grísla frá 2 daga til að koma í veg fyrir dauðsföll og draga úr klínískum einkennum um bjúgsjúkdóma (af völdum verotoxins 2e framleitt af e. coli) og til að draga úr tapi á daglegri þyngdaraukningu á lokunartímabilinu í ljósi sýkinga með verotoxin 2e sem framleiða e. coli til slátrunar frá 164 daga aldri.

Suvaxyn Circo Evrópusambandið - íslenska - EMA (European Medicines Agency)

suvaxyn circo

zoetis belgium sa - svín circovirus bóluefni (óvirkt, skal læknir hafa) - immunologicals for suidae, inactivated viral vaccines - svín (fyrir fitandi) - fyrir virk bólusetningar svín frá 3 vikur aldri gegn svín circovirus tegund 2 (pcv2) til að draga úr veiru hlaða í blóði og eitilfruma vefi og fecal úthella af völdum sýkinga með pcv2.

Vectormune FP ILT + AE Evrópusambandið - íslenska - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kjúklingur - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Enteroporc Coli AC Evrópusambandið - íslenska - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svín - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.